CEO total compensation of $10.2 million is within a reasonable range for a healthcare/packaging company of Aptar's $7.9B market cap, with the company's own benchmarking placing total direct compensation between the 50th and 75th percentiles of its peer group — not materially above the +20% CEO threshold. The pay structure is well-designed: 75% of the long-term equity grant is performance-based (50% in performance stock awards tied to 3-year adjusted return on invested capital with a relative total shareholder return modifier, plus 25% in stock options that only have value if the stock price rises), the annual short-term incentive is tied to measurable EBITDA, sales growth, and cost-efficiency metrics, and the company maintains a formal clawback policy. Prior-year shareholder support was an overwhelming 96.2%, well above the 70% threshold, and ATR's 3-year stock return of +13.4% outperforms the compensation peer group median of -19.1% by +32.5pp, indicating that above-benchmark incentive pay — if any — was earned alongside strong relative shareholder returns.

PwC has audited Aptar's financial statements for over 30 years, which exceeds the 25-year tenure threshold in the voting policy that triggers an against vote due to concerns about auditor independence and professional skepticism. On the fee ratio test, non-audit fees (audit-related fees of $223,900 plus all other fees of $27,200, totaling $251,100) represent approximately 5.3% of core audit fees of $4,732,662, which is well within the 50% limit and raises no independence concern on that dimension. However, the confirmed tenure of over 30 years alone is sufficient under the policy to vote against, and while the proxy notes annual lead partner rotation every five years, no active multi-year firm rotation plan is disclosed — the audit committee's rationale centers on continuity and familiarity rather than a concrete remediation commitment.